Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Pancreatic Neoplasms × Neoadjuvant Therapy × Clear all

Phase

Phase 2 7 Phase 3 3 Phase 2/3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Squamous Cell Carcinoma 3 Squamous Cell Carcinoma of Head and Neck 2 Head and Neck Neoplasms 2 Esophageal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Vomiting 1 Urologic Neoplasms 1 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Nausea 1 Lung Neoplasms 1 Klatskin Tumor 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Breast Neoplasms 1 Adenocarcinoma, Bronchiolo-Alveolar 1 Adenocarcinoma of Lung 1 Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 83 130-nm albumin-bound paclitaxel 41 Albumin-Bound Paclitaxel 31 Oxaliplatin 23 Fluorouracil 23 Capecitabine 18 Leucovorin 17 pembrolizumab 16 Taxes 16 Cyclophosphamide 16 Irinotecan 14 Cetuximab 11 Bevacizumab 11 fludarabine 9 Nivolumab 9 Cisplatin 9 durvalumab 7 Radiotherapy 7 spartalizumab 6 aldesleukin 6 Radiosurgery 6 Paclitaxel 6 irinotecan sucrosofate 5 avelumab 5 Injections 5 Erlotinib Hydrochloride 5 ALT-803 5 folfirinox 4 Ipilimumab 4 Immunotherapy, Adoptive 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02305186 2021-08-13

UVA-PC-PD101

University of Virginia

Phase 1/2 Unknown

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡